1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Bristol-Myers sues Merck in US over PD-1 patent

 
• By Mandy Jackson

Bristol-Myers Squibb received US patent protection for methods of treating cancer with an antibody that inhibits programmed cell death-1 (PD-1) in May, but waited until Merck & Co's Keytruda (pembrolizumab) won US FDA approval for melanoma to sue for patent infringement.

Bristol-Myers Squibb received US patent protection for methods of treating cancer with an antibody that inhibits programmed cell death-1 (PD-1) in May, but waited until Merck & Co's Keytruda (pembrolizumab) won US FDA approval for melanoma to sue for patent infringement.

Bristol-Myers had the first PD-1 inhibitor approved anywhere in the world when the company and its partner Ono Pharmaceuticals won Japanese approval for Opdivo (nivolumab) to treat melanoma in July,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 
• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

ASCO: Zepzelca Tecentriq Combo A Lung Cancer Success For Jazz and Roche

 
• By Andrew McConaghie

Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.

More from Therapy Areas

ASCO: Zepzelca Tecentriq Combo A Lung Cancer Success For Jazz and Roche

 
• By Andrew McConaghie

Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.